Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®

June 5, 2011 By Bio-Medicine.Org

CHICAGO, June 5, 2011 /PRNewswire/ — Nektar Therapeutics
(Nasdaq:
NKTR
) today announced positive results from a subpopulation of
patients in a Phase 2 clinical study evaluating single-agent
NKTR-102 in women with platinum-resistant/refractory ovarian
cancer.  A total of 33 women in the study with prior
Doxil® (pegylated liposomal doxorubicin or PLD) treatment were
evaluable for response rate using either RECIST 1.0 criteria
(response by tumor imaging) or Gynecologic Cancer InterGroup (GCIG)
criteria, which is a combination of RECIST and/or ovarian cancer
biomarker (CA-125) criteria.(1)  Confirmed and unconfirmed
objective response rates using RECIST were 25 percent (4/16) and 29
percent (4/14) for the q14d and q21d dose schedules, respectively.
 Confirmed objective response rates using RECIST were 19
percent (3/16) and 21 percent (3/14) for each dose schedule,
respectively.  GCIG (confirmed and unconfirmed) response rates
were 50 percent (8/16) in the once every 14 days (q14d) dose
schedule and 35 percent (6/17) for the once every 21 days (q21d)
dose schedule.  Confirmed objective GCIG response rates were
38 percent (6/16) and 35 percent (6/17) in the q14d and q21d dose
schedules, respectively.

Median progression-free survival for all 33 patients in the
subpopulation previously treated with PLD was 5.4 months and median
overall survival was 13.9 months.  The median duration of
confirmed response was 4.2 months in the q14d schedule and 4.4
months in the q21d schedule.

“NKTR-102 exhibits an exceptionally high response rate and long
median survival compared to what would be expected in this group of
heavily pre-treated women with platinum-resistant and refractory
ovarian cancer,” said Dr. Agustin Garcia, Associate Professor of
Clinical Medicine at USC Norris Comprehensive Center.  “Women
whose cancer has progressed following trea

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech